TNFAIP3 Polyclonal Antibody
- Size: 100ul
- Application: ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC)
- Reactivity: Human, Mouse, Rat
- Predicted Reactivity: Dog, Cow, Pig, Horse
-
Datasheet
Tech Support
IMAGES
Formalin-fixed and paraffin embedded rat myocardium labeled with Anti-TNFAIP3 Polyclonal Antibody, Unconjugated (bs-2803R) at 1:200 followed by conjugation to the secondary antibody and DAB staining
Formalin-fixed and paraffin embedded human lung carcinoma labeled with Rabbit Anti TNFAIP3/A20 Polyclonal Antibody, Unconjugated (bs-2803R) at 1:200 followed by conjugation to the secondary antibody and DAB staining
PRODUCT DETAILS
SPECIFICATIONS |
|
|---|---|
|
PRODUCT NAME |
TNFAIP3 Polyclonal Antibody |
|
CONJUGATION |
Unconjugated |
|
HOST |
Rabbit |
| SOURCE |
KLH conjugated synthetic peptide derived from human TNFAIP3 |
| IMMUNOGEN RANGE |
51-150/790 |
| CLONALITY |
Polyclonal |
| ISOTYPE |
IgG |
| CONCENTRATION |
1ug/ul |
| PURIFICATION |
Purified by Protein A. |
| STORAGE BUFFER |
Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. |
| STORAGE CONDITION |
Store at -20°C for 12 months.. |
TARGET |
|
|---|---|
| GENE ID |
|
| SUBCELLULAR LOCATION |
Cytoplasm, Nucleus |
| SYNONYMS |
A20; OTUD7C; TNFA1P2; Tumor necrosis factor alpha-induced protein 3; TNF alpha-induced protein 3; OTU domain-containing protein 7C; Putative DNA-binding protein A20; Zinc finger protein A20; TNFAIP3 |
| BACKGROUND |
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. |
| APPLICATION DILUTION |
ELISA(1:500-1000), IHC-P(1:200-400), IHC-F(1:100-500), IF(IHC-P)(1:50-200), IF(IHC-F)(1:50-200), IF(ICC)(1:50-200) |
